\-\ Texto\\:\\ \ \(0\)\
\-\ macrocephay\ \(0\)\
\-\ diffuse\\,\\ symmetric\\ involvement\\ of\\ cerebral\\ white\\ matter\ \(0\)\
\-\ subcortical\\ white\\ matter\\ preferentially\\ affected\\ early\ \(0\)\
\-\ no\\ contrast\\ enhancement\ \(2\)\
\-\ mrs\\:\\ elevation\\ of\\ naa\ \(0\)\
\-\ canavan\\ disease\ \(0\)\
\-\ alexander\\ disease\ \(0\)\
\-\ canavan\\ disease\ \(0\)\
\-\ metachromatic\\ leukodystrophy\ \(1\)\
\-\ 2\\ y\\.o\\.\\ girl\\ whose\\ parents\\ noted\\ irritability\\ in\\ early\\ neonatal\\ course\\.\\ \\ this\\ improved\\ by\\ 5\\ months\\ of\\ age\\ when\\ patient\\ was\\ noted\\ to\\ be\\ hypotonic\\.\ \(0\)\
\-\ she\\ was\\ also\\ diagnosed\\ in\\ infancy\\ with\\ cortical\\ blindness\\ and\\ has\\ developmentally\\ delay\\.\\ \\ head\\ size\\ noted\\ to\\ be\\ large\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ canavan\\:\\ 0\\.20305928108516383\ \(0\)\
\-\ macrocephay\\:\\ 0\\.11019398029958123\ \(0\)\
\-\ mrs\\:\\ 0\\.10152964054258191\ \(0\)\
\-\ metachromatic\\:\\ 0\\.10152964054258191\ \(0\)\
\-\ alexander\\:\\ 0\\.0928653007855826\ \(0\)\
\-\ hypotonic\\:\\ 0\\.0928653007855826\ \(0\)\
\-\ preferentially\\:\\ 0\\.08779698693423055\ \(0\)\
\-\ naa\\:\\ 0\\.08779698693423055\ \(0\)\
\-\ leukodystrophy\\:\\ 0\\.08779698693423055\ \(0\)\
\-\ developmentally\\:\\ 0\\.08587010343638982\ \(0\)\
\-\ matter\\:\\ 0\\.08411199926001994\ \(0\)\
\-\ irritability\\:\\ 0\\.07913264717723123\ \(0\)\
\-\ infancy\\:\\ 0\\.07813211333131202\ \(0\)\
\-\ early\\:\\ 0\\.07812897424106095\ \(0\)\
\-\ whose\\:\\ 0\\.0763433527858036\ \(0\)\
\-\ blindness\\:\\ 0\\.0763433527858036\ \(0\)\
\-\ noted\\:\\ 0\\.07595329456697227\ \(0\)\
\-\ white\\:\\ 0\\.07085260531780045\ \(0\)\
\-\ subcortical\\:\\ 0\\.06505750639152842\ \(0\)\
\-\ neonatal\\:\\ 0\\.06408298712315702\ \(0\)\
\-\ parents\\:\\ 0\\.0620671352782055\ \(0\)\
\-\ delay\\:\\ 0\\.053010093068288945\ \(0\)\
\-\ elevation\\:\\ 0\\.05275498217289886\ \(0\)\
\-\ disease\\:\\ 0\\.0523776577955889\ \(0\)\
\-\ improved\\:\\ 0\\.050882328695040606\ \(0\)\
\-\ symmetric\\:\\ 0\\.04878579422788058\ \(0\)\
\-\ affected\\:\\ 0\\.04621905764437179\ \(0\)\
\-\ course\\:\\ 0\\.04030664304319552\ \(0\)\
\-\ diagnosed\\:\\ 0\\.03927743945993757\ \(0\)\
\-\ involvement\\:\\ 0\\.03914923320784771\ \(0\)\
\-\ cortical\\:\\ 0\\.03893843563219765\ \(0\)\
\-\ girl\\:\\ 0\\.037554717887372475\ \(0\)\
\-\ cerebral\\:\\ 0\\.037005581272050884\ \(0\)\
\-\ size\\:\\ 0\\.03581094839223464\ \(0\)\
\-\ be\\:\\ 0\\.03294391808359823\ \(0\)\
\-\ age\\:\\ 0\\.032511379069303833\ \(0\)\
\-\ diffuse\\:\\ 0\\.03233759275469144\ \(0\)\
\-\ 5\\:\\ 0\\.031252005280552046\ \(0\)\
\-\ y\\.o\\:\\ 0\\.030829742907333754\ \(0\)\
\-\ when\\:\\ 0\\.030591640470200073\ \(0\)\
\-\ head\\:\\ 0\\.030295016382173703\ \(0\)\
\-\ she\\:\\ 0\\.029984826768177153\ \(0\)\
\-\ months\\:\\ 0\\.02917426618362584\ \(0\)\
\-\ enhancement\\:\\ 0\\.02863110957653795\ \(0\)\
\-\ was\\:\\ 0\\.024706938055342173\ \(0\)\
\-\ contrast\\:\\ 0\\.023909696085098818\ \(0\)\
\-\ large\\:\\ 0\\.023356780397888497\ \(0\)\
\-\ 2\\:\\ 0\\.023001306206381827\ \(0\)\
\-\ also\\:\\ 0\\.021057744920876892\ \(0\)\
\-\ has\\:\\ 0\\.020058749631178475\ \(0\)\
\-\ by\\:\\ 0\\.017785886290560934\ \(0\)\
\-\ \\:\\:\\ 0\\.014128435199883313\ \(0\)\
\-\ this\\:\\ 0\\.012014215166426664\ \(0\)\
\-\ no\\:\\ 0\\.010755551883797525\ \(0\)\
\-\ patient\\:\\ 0\\.01070739913645485\ \(0\)\
\-\ to\\:\\ 0\\.010676702711074657\ \(0\)\
\-\ in\\:\\ 0\\.010534930753506373\ \(0\)\
\-\ of\\:\\ 0\\.004368892529924566\ \(0\)\
\-\ \\,\\:\\ 0\\.0033838758189660926\ \(0\)\
\-\ and\\:\\ 0\\.0022501125716527307\ \(0\)\
\-\ \\.\\:\\ 0\\.002218721006084142\ \(0\)\
\-\ with\\:\\ 0\\.0014625522011236219\ \(0\)\
